Search filters

Filters
Clear All

Phase

  • 1
  • 3
  • 1
  • 6
  • 12
  • 6
  • 12

Found 12 Pancreatitis trials

A listing of Pancreatitis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

The Role of the Microbiome in Inter-Individual Variability in NSAID Disposition and Response

18-99 years
All genders
Phase 1
Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used in the treatment of pain and inflammation. Mounting evidence indicates that rectal administration of NSAIDs is also effective in preventing pancreatitis following endoscopic retrograde cholangiopancreatography (ERCP) by an unknown mechanism. Alterations in the salivary and fecal microbiome have been observed in patients with …
 The Cancer of the Pancreas Screening-5

The Cancer of the Pancreas Screening-5

1-99 years
All genders
The specific Aims of CAPS5 will be: Aim #1: To evaluate pancreatic fluid mutations and circulating pancreatic epithelial cells as accurate markers of neoplasia by comparing their prevalence in cases with sporadic pancreatic neoplasia to healthy and disease controls. Aim #2: To compare the prevalence of pancreatic fluid mutations and …
 APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1  BRCA2 or PALB2 Mutation

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1 BRCA2 or PALB2 Mutation

18-99 years
All genders
The purpose of this study is to compare the usual treatment alone to using one year of olaparib. We will enroll subject who have been diagnosed with pancreatic cancer and have undergone surgery to remove the cancer. Only patients who are found to have a BRCA1, BRCA2 or PALB2 mutation …

Effect of GLP-1 Agonist Therapy on Insulin Secretion in Adults with Pancreatic Insufficient Cystic Fibrosis and Abnormal Glucose Tolerance: a randomized open-label cross-over trial

18-50 years
All genders
Diabetes is a major co-morbidity in pancreatic insufficient cystic fibrosis (PI-CF) and associated with worse outcomes. While reduced -cell mass contributes to the insulin secretory defects that characterizes cystic fibrosis-related diabetes (CFRD), other modifiable determinants appear operative in the emergence and progression of abnormal glucose tolerance towards diabetes. Identifying interventions …

UPCC 04223: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of BI 907828 for treatment of patients with locally advanced / metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours

All genders
This study is open to adults with advanced cancer in the biliary tract, pancreas, lung, or bladder for whom previous treatment was not successful or no treatment exists, to find out whether a medicine called BI 907828 helps. BI 907828 is a so-called MDM2 inhibitor that is being developed to …
 Does Apolipoprotein A-V (APOA5) the genetic code of a protein, affect the levels of triglycerides (a type of fat) in the blood,

Does Apolipoprotein A-V (APOA5) the genetic code of a protein, affect the levels of triglycerides (a type of fat) in the blood,

18-99 years
All genders
The purpose of this study is to determine how changes in the genetic code of a protein called Apolipoprotein A-V (APOA5) may affect the levels of triglycerides (a type of fat) in the blood, and the risk of heart disease and acute pancreatitis. People who have these changes, as well …
 Precision Promise Platform Trial for Metastatic Pancreatic Cancer

Precision Promise Platform Trial for Metastatic Pancreatic Cancer

All genders
Precision Promise is a multi-center, seamless Phase 2/3 platform trial designed to evaluate multiple regimens in metastatic pancreatic cancer. The goal of the platform is to find effective therapies for pancreatic cancer. The platform will rapidly and efficiently test multiple novel drugs and combinations compared to standard of care therapy …
 huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer

huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer

18-99 years
All genders
Phase 1
This is a Phase I study evaluating the safety and feasibility of lentiviral transduced huCART-meso cells when given in combination with VCN-01 in a 3+3 dose (de)escalation design.
 REVOLUTION: Trial to Evaluate Immunotherapy Combinations with Chemotherapy for the Treatment of Patients with Previously Untreated Metastatic Pancreatic Adenocarcinoma

REVOLUTION: Trial to Evaluate Immunotherapy Combinations with Chemotherapy for the Treatment of Patients with Previously Untreated Metastatic Pancreatic Adenocarcinoma

18-99 years
All genders
Phase 1
This is a phase 1 study that enrolls subjects with metastatic pancreatic adenocarcinoma. The purpose of this study is to learn about the safety and efficacy of a combination of 4 study drugs: ipilimumab (ipi), nab-paclitaxel (nP), gemcitabine (gem), and hydroxychloroquine (HCQ). This is an open-label, non-randomized, exploratory platform trial …

A Study to Evaluate the Efficacy and Safety of Belzutifan Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET)

12-99 years
All genders
Phase 2
Interventional
This is a study to evaluate the efficacy and safety of Belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL) or pancreatic neuroendocrine tumor (pNET). The primary objective of the study is to evaluate the objective response rate (ORR) of belzutifan per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST …
1 - 10 of 12